Overview

Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development and knowledge services. With combined revenue pro... More >>

Recent NewsMore >>
DateTitle 
09/20/16LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 20, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, today announced that veteran biopharmaceutical executive John Ratliff will succeed Deborah Keller as CEO of Covance Drug Development, effective October 1. Ratliff will be a member of the LabCorp executive committee and will report to David P. King, chairman and CEO of LabCorp. Th... 
Printer Friendly Version
09/16/16LabCorp Subsidiary Sequenom Inc. Announces Tender Offers and Consent Solicitations for 5% Convertible Senior Notes Due 2017 and 5% Convertible Senior Exchange Notes Due 2018
BURLINGTON, N.C. & SAN DIEGO--(BUSINESS WIRE)--Sep. 16, 2016-- Sequenom, Inc., a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), announced the commencement of cash tender offers (the “Tender Offers”) for any and all of the outstanding 5% Convertible Senior Notes Due 2017 (CUSIP No. 817337 AB4, the “2017 Notes”) and 5% Convertible Senior Exchange Notes Due 2018 (CUSIP No. 817337 AC2, the “2018 Notes” and, ... 
Printer Friendly Version
09/12/16LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 12, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that for the period of September 12, 2016 to March 10, 2017, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading ... 
Printer Friendly Version
09/07/16Laboratory Corporation of America® Holdings Successfully Completes Acquisition of Sequenom, Inc.
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 7, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the successful completion of the offering period for the cash tender offer by its direct wholly owned subsidiary, Savoy Acquisition Corp. (Purchaser), for all outstanding shares of common stock of Sequenom, Inc. (NASDAQ: SQNM) (Sequenom), including the associated preferred stock purchase rights (together with the common ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
LH (Common)
ExchangeNYSE
Price$135.46
Change Stock is Down 1.43
Intraday High$137.10
Intraday Low$134.67
Volume447,619
Data as of 09/29/16
4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2015 Annual Report

2014 Annual Report

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release